The endeavor of drug discovery and development for infectious diseases represents a critical frontier in modern medicine, driven by the ongoing threat of emerging pathogens and antimicrobial resistance. This multifaceted process begins with target identification, where researchers identify vulnerabilities within microbial pathogens that can be exploited for therapeutic intervention. Armed with this knowledge, scientists employ an array of innovative approaches, including virtual screening, fragment-based drug design, and structure-based drug discovery, to identify and optimize lead compounds with potent antimicrobial activity. Subsequent preclinical studies rigorously assess the safety, efficacy, and pharmacokinetics of candidate compounds, guiding the selection of promising candidates for clinical evaluation. Through a collaborative effort involving academia, industry partners, and regulatory agencies, these candidates advance through the clinical trial pipeline, with the ultimate goal of delivering safe and efficacious therapies to address the evolving landscape of infectious diseases and improve global public health outcomes.